Francesco Massari
Feb 18, 2025, 12:22
Francesco Massari: Are we sure that the Parpi are for all patients or just selected ones?
Francesco Massari, Medical Oncologist focused on Genitourinary Cancer at The University Hospital of Bologna IRCCS, shared a post on X:
“Fantastic results by Talapro-2 trial about the combination talazoparib and enzalutamide in 1st line mCRPC.
But.. are we sure that the Parpi are for all patients or just selected ones?”
Quoting Tom Powles‘s post:
“TALAPR02 looks at Talazoparib/enza vs enza in 1st line CRPC.
It has significant OS in ITT HR=0.796. It’s current used in HRR deficient.
Subset analysis and wider data still supports the HRR biomarker OS (HRR deficient HR -0.54, HRR non-defficent/NA 0.87), but ITT OS is +ve.”\
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 18, 2025, 19:27
Feb 18, 2025, 19:12
Feb 18, 2025, 19:03
Feb 18, 2025, 18:55
Feb 18, 2025, 18:13
Feb 18, 2025, 17:57
Feb 18, 2025, 17:36